BioMimetic Ramps Up R&D For Synthetic Bone Products
This article was originally published in The Gray Sheet
Executive Summary
Combination products firm BioMimetic expects rapid enrollment this fall in a U.S. pivotal study of a product to facilitate fusions in the foot and ankle, CEO Samuel Lynch said during an Aug. 14 earnings call
You may also be interested in...
BioMimetic Aims To Complete Bone Graft Study Enrollment By Year-End
BioMimetic Therapeutics is hoping enrollment in an ongoing pivotal trial for its Augment Bone Graft will be complete by year-end despite a recent slowdown in registration
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.